Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. - Test2 - elhamkhani - TriplyDB

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

http://www.wikidata.org/entity/Q33379689

about

New viruses for cancer therapy: meeting clinical needs Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Thunder and lightning: immunotherapy and oncolytic viruses collide Intelligent design: combination therapy with oncolytic viruses Oncolytic virus therapy: A new era of cancer treatment at dawn Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications Going viral: a review of replication-selective oncolytic adenoviruses Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data Oncolytic virotherapy of canine and feline cancer Role of microRNAs in hepatocellular carcinoma: a clinical perspective Trial Watch:: Oncolytic viruses for cancer therapy Oncolytic viruses as anticancer vaccines Design and development of a robotized system coupled to µCT imaging for intratumoral drug evaluation in a HCC mouse model Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.Viruses as nanomedicine for cancer Trial Watch-Oncolytic viruses and cancer therapy Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors Targeting tumor vasculature with an oncolytic virus.Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1 Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.Inhibitors of C5 complement enhance vaccinia virus oncolysis.Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.Synergistic interaction between oncolytic viruses augments tumor killing.Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.

P2860

Q24567699-3D011296-10B3-48C0-9279-DBA5899C3213 Q24596171-95075B11-2778-4071-9403-1D3A3590DDD2 Q24597894-427DF3A6-EA3B-4422-B74B-9D3961CE436E Q24628227-3F3CACFA-0419-44AD-9C13-1926D1D7F551 Q26739714-9080A025-9A55-4143-BCF5-D49E7D252F2B Q26752807-64BCED76-4CC7-4E86-AF06-9EAA255FF9EA Q26766798-C3E42335-8420-49AF-B77A-CE0003855D34 Q26775030-2220A978-14D7-4989-9A1B-D907CD4E6AC1 Q26776553-0EEA6262-8565-47DB-9E7D-06CC3666E8AC Q26797520-272EF416-844A-4FAE-AA46-DDF8365B25B1 Q26801501-9576EDA9-C22C-4CF2-BAAC-B1B438B4F880 Q27008306-564B9F12-6209-44C7-B02B-5BD4B522550E Q27014034-E8ECA322-B61A-46DA-B97A-A412F0B9E180 Q27021951-26638AEF-572D-4935-BCF5-E6D7FD785727 Q27025600-CB35885C-7F1C-4D2B-BF49-E30AACE945C2 Q27312299-F9D73440-C4BD-4AF6-8AE5-8FB0FB93FD8A Q27323196-A2647E36-01AE-4E09-9A71-F3E5AC56A877 Q27690636-2A6ECEB5-46FA-4446-8E4D-D3E0D28A1AD3 Q28072347-E25B5BA4-1DCB-42AF-99DE-B23D5980E43C Q28086999-C6019FC6-D830-41B2-B6A3-57CFF81387F8 Q30500348-7406BD2F-4EA1-462F-9749-E4E0CAB4F14C Q33558337-10F08E9A-4314-4C5A-9634-18AD8F268EEB Q33579883-DE6F74BA-95E7-4790-9614-BF2AFA1B467B Q33635033-7E0B9EA0-D69D-4A88-8B13-AB0F3B14DAF9 Q33710420-E6B934BF-1D4C-4F20-9412-989B5D0D0B4D Q33713908-A863C6F0-B3C5-4BA5-95FA-CD8C46B6EADF Q33768177-7752C9FB-DB08-4A43-941F-8BC0DBD54B11 Q33769835-6CA9D2B8-B607-46B0-A911-B281F1670341 Q33808504-1361BE3F-0BD6-4226-A675-199FA26A7CA4 Q33924515-9E686099-6E84-4549-941E-EEEBEC9FBF02 Q33931616-36A8C035-A0F3-4E99-A57B-992019EF4283 Q33931640-B43A0B67-18D7-4570-B28E-CAF6E865DE6A Q34020594-3BDE0550-3210-45A6-B9AD-AB4DAE8E2BC9 Q34183436-E32E388D-CE29-4CE2-BD61-6ED36EACAD40 Q34212910-15CCE193-8A62-4852-A694-5581DD9C1697 Q34223150-5698F0D9-B4F1-42BE-8494-EED041CF286D Q34327051-A0617C72-4571-48F1-8716-60F27378B2AC Q34343742-BCF8BA72-133D-4553-B35B-0CC1AE485EBA Q34343768-FB8529F8-F58A-44C1-A9F5-9CA658028FC2 Q34585684-FFBBC6B4-3ED0-49C9-A478-E5957C5A1044

P2860

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

http://www.wikidata.org/entity/Q33379689

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Use of a targeted oncolytic po ...... liver cancer: a phase I trial.

@ast

Use of a targeted oncolytic po ...... liver cancer: a phase I trial.

@en

type

label

Use of a targeted oncolytic po ...... liver cancer: a phase I trial.

@ast

Use of a targeted oncolytic po ...... liver cancer: a phase I trial.

@en

prefLabel

Use of a targeted oncolytic po ...... liver cancer: a phase I trial.

@ast

Use of a targeted oncolytic po ...... liver cancer: a phase I trial.

@en

P1433

Q33379689-AEC5CCFE-C744-456B-9E93-DF6430D13E2C

P1476

Q33379689-456473E9-1D3F-4133-9CF7-7FC1CEF5C37D

P2093

Q33379689-01A8BA0A-2B64-4F0F-86F4-997F9AADD42A

Q33379689-15149BB2-33AA-4F40-AF6F-7465763B5D81

Q33379689-2793787E-8323-482B-ACD0-92509E3C7649

Q33379689-2BFA55D7-757C-46DC-AD3E-12227B49C55E

Q33379689-3EEE18FA-D39B-416E-BE34-F4DF81287016

Q33379689-4FB0BE20-9893-4F79-B829-E9699CED6147

Q33379689-57EC83D3-A5E6-4F63-8A07-440390DF49F7

Q33379689-67282B66-B175-47BC-A5CB-D0320DE0ABA8

Q33379689-73E90078-E13F-4A1F-8346-FFC05980A10C

Q33379689-82A2120C-D634-4F47-8E35-39EB1E855B5B

P304

Q33379689-AB2BE1A4-97A9-4F1D-B880-BA0B71AB3A07

P31

Q33379689-D482E925-C230-409F-8383-B6920564F7CF

P356

Q33379689-C36CE5C5-A038-4208-BC1F-0E68B68068D1

P433

Q33379689-61861C88-5018-4138-AB47-84CD7CA32713

P478

Q33379689-EBB00779-CFA6-42AB-B8D3-1824FA1466AE

P50

Q33379689-55128750-C102-4B07-848B-EF39664A3E25

Q33379689-DA6E0D94-1986-446E-AE56-BD745F3D6559

P577

Q33379689-D946C148-6D7A-4E8A-B6DA-43D75CF03EF4

P698

Q33379689-313CF3DD-442D-4F00-BBCE-139D5CBEBDD2

P921

Q33379689-12695997-841B-4E82-8191-E3BAFBD1B679

Q33379689-BDD66B00-6F1E-4AC6-986B-7A34ABF33DCF

P356

S1470-2045(08)70107-4

P1433

The Lancet Oncology

P1476

Use of a targeted oncolytic po ...... liver cancer: a phase I trial.

@en

P2093

Anne Moon

http://www.w3.org/2001/XMLSchema#string

Byeong-Ho Park

http://www.w3.org/2001/XMLSchema#string

Byung Geon Rhee

http://www.w3.org/2001/XMLSchema#string

Chohee Park

http://www.w3.org/2001/XMLSchema#string

Daniel Y Sze

http://www.w3.org/2001/XMLSchema#string

David H Kirn

http://www.w3.org/2001/XMLSchema#string

Herbert M Pinedo

http://www.w3.org/2001/XMLSchema#string

Hyuk-Chan Kwon

http://www.w3.org/2001/XMLSchema#string

Jae-Seok Kim

http://www.w3.org/2001/XMLSchema#string

Jin-Han Yoon

http://www.w3.org/2001/XMLSchema#string

P304

533-542

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(08)70107-4

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18495536

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

phase I clinical trial